vs
Apellis Pharmaceuticals, Inc.（APLS）与Sweetgreen, Inc.（SG）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Sweetgreen, Inc.的1.3倍（$199.9M vs $155.2M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -32.0%，领先2.6%），Sweetgreen, Inc.同比增速更快（-3.5% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-39.0M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -0.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Sweetgreen是美国一家主打沙拉产品的休闲快餐连锁品牌，由三位创始人于2006年11月创立。三位创始人从乔治城大学麦克唐纳商学院毕业三个月后，于2007年8月在华盛顿特区开设了品牌第一家门店，目前在北美多地拥有门店布局。
APLS vs SG — 直观对比
营收规模更大
APLS
是对方的1.3倍
$155.2M
营收增速更快
SG
高出2.4%
-5.9%
净利率更高
APLS
高出2.6%
-32.0%
自由现金流更多
APLS
多$24.7M
$-39.0M
两年增速更快
APLS
近两年复合增速
-0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $155.2M |
| 净利润 | $-59.0M | $-49.7M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -31.0% |
| 净利率 | -29.5% | -32.0% |
| 营收同比 | -5.9% | -3.5% |
| 净利润同比 | -62.2% | -71.3% |
| 每股收益（稀释后） | $-0.40 | $-0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSG
| Q4 25 | $199.9M | $155.2M | ||
| Q3 25 | $458.6M | $172.4M | ||
| Q2 25 | $178.5M | $185.6M | ||
| Q1 25 | $166.8M | $166.3M | ||
| Q4 24 | $212.5M | $160.9M | ||
| Q3 24 | $196.8M | $173.4M | ||
| Q2 24 | $199.7M | $184.6M | ||
| Q1 24 | $172.3M | $157.8M |
净利润APLSSG
| Q4 25 | $-59.0M | $-49.7M | ||
| Q3 25 | $215.7M | $-36.1M | ||
| Q2 25 | $-42.2M | $-23.2M | ||
| Q1 25 | $-92.2M | $-25.0M | ||
| Q4 24 | $-36.4M | $-29.0M | ||
| Q3 24 | $-57.4M | $-20.8M | ||
| Q2 24 | $-37.7M | $-14.5M | ||
| Q1 24 | $-66.4M | $-26.1M |
营业利润率APLSSG
| Q4 25 | -25.6% | -31.0% | ||
| Q3 25 | 48.7% | -21.0% | ||
| Q2 25 | -18.6% | -14.2% | ||
| Q1 25 | -50.0% | -17.2% | ||
| Q4 24 | -12.3% | -19.5% | ||
| Q3 24 | -24.0% | -12.2% | ||
| Q2 24 | -14.7% | -8.8% | ||
| Q1 24 | -36.0% | -17.1% |
净利率APLSSG
| Q4 25 | -29.5% | -32.0% | ||
| Q3 25 | 47.0% | -21.0% | ||
| Q2 25 | -23.6% | -12.5% | ||
| Q1 25 | -55.3% | -15.1% | ||
| Q4 24 | -17.1% | -18.0% | ||
| Q3 24 | -29.2% | -12.0% | ||
| Q2 24 | -18.9% | -7.8% | ||
| Q1 24 | -38.5% | -16.5% |
每股收益（稀释后）APLSSG
| Q4 25 | $-0.40 | $-0.42 | ||
| Q3 25 | $1.67 | $-0.31 | ||
| Q2 25 | $-0.33 | $-0.20 | ||
| Q1 25 | $-0.74 | $-0.21 | ||
| Q4 24 | $-0.30 | $-0.25 | ||
| Q3 24 | $-0.46 | $-0.18 | ||
| Q2 24 | $-0.30 | $-0.13 | ||
| Q1 24 | $-0.54 | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $89.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $356.1M |
| 总资产 | $1.1B | $788.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSG
| Q4 25 | $466.2M | $89.2M | ||
| Q3 25 | $479.2M | $130.0M | ||
| Q2 25 | $370.0M | $168.5M | ||
| Q1 25 | $358.4M | $183.9M | ||
| Q4 24 | $411.3M | $214.8M | ||
| Q3 24 | $396.9M | $234.6M | ||
| Q2 24 | $360.1M | $244.6M | ||
| Q1 24 | $325.9M | $243.8M |
总债务APLSSG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSSG
| Q4 25 | $370.1M | $356.1M | ||
| Q3 25 | $401.2M | $393.3M | ||
| Q2 25 | $156.3M | $423.3M | ||
| Q1 25 | $164.2M | $432.8M | ||
| Q4 24 | $228.5M | $446.1M | ||
| Q3 24 | $237.1M | $463.3M | ||
| Q2 24 | $264.3M | $470.1M | ||
| Q1 24 | $266.7M | $470.3M |
总资产APLSSG
| Q4 25 | $1.1B | $788.1M | ||
| Q3 25 | $1.1B | $824.8M | ||
| Q2 25 | $821.4M | $831.9M | ||
| Q1 25 | $807.3M | $834.3M | ||
| Q4 24 | $885.1M | $856.8M | ||
| Q3 24 | $901.9M | $858.0M | ||
| Q2 24 | $904.5M | $859.2M | ||
| Q1 24 | $831.9M | $842.7M |
负债/权益比APLSSG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-8.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-39.0M |
| 自由现金流率自由现金流/营收 | -7.1% | -25.1% |
| 资本支出强度资本支出/营收 | 0.1% | 19.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-119.2M |
8季度趋势，按日历期对齐
经营现金流APLSSG
| Q4 25 | $-14.2M | $-8.7M | ||
| Q3 25 | $108.5M | $-1.4M | ||
| Q2 25 | $4.4M | $10.5M | ||
| Q1 25 | $-53.4M | $-13.1M | ||
| Q4 24 | $19.4M | $6.1M | ||
| Q3 24 | $34.1M | $14.7M | ||
| Q2 24 | $-8.3M | $19.1M | ||
| Q1 24 | $-133.0M | $3.4M |
自由现金流APLSSG
| Q4 25 | $-14.3M | $-39.0M | ||
| Q3 25 | $108.3M | $-37.2M | ||
| Q2 25 | $4.4M | $-13.1M | ||
| Q1 25 | $-53.4M | $-29.9M | ||
| Q4 24 | $19.3M | $-20.6M | ||
| Q3 24 | — | $-10.3M | ||
| Q2 24 | $-8.4M | $-156.0K | ||
| Q1 24 | $-133.3M | $-10.0M |
自由现金流率APLSSG
| Q4 25 | -7.1% | -25.1% | ||
| Q3 25 | 23.6% | -21.6% | ||
| Q2 25 | 2.5% | -7.1% | ||
| Q1 25 | -32.0% | -18.0% | ||
| Q4 24 | 9.1% | -12.8% | ||
| Q3 24 | — | -6.0% | ||
| Q2 24 | -4.2% | -0.1% | ||
| Q1 24 | -77.3% | -6.3% |
资本支出强度APLSSG
| Q4 25 | 0.1% | 19.6% | ||
| Q3 25 | 0.0% | 20.8% | ||
| Q2 25 | 0.0% | 12.7% | ||
| Q1 25 | 0.0% | 10.1% | ||
| Q4 24 | 0.0% | 16.6% | ||
| Q3 24 | 0.0% | 14.4% | ||
| Q2 24 | 0.0% | 10.4% | ||
| Q1 24 | 0.2% | 8.5% |
现金转化率APLSSG
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SG
暂无分部数据
